Polycystic ovary syndrome (PCOS) affects up to 15% of women of reproductive age and is characterized by hyperandrogenism, menstrual disturbance, anovulatory infertility and obesity. A large body of evidence has indicated that increased insulin resistance and compensatory hyperinsulinaemia play a key role in the pathogenesis of PCOS.
Methods
The Cochrane Library, MEDLINE, Cumulative Index to Nursing and Allied Health Literature and EMBASE were searched up to October 2011 for randomized trials compared metformin with placebo or no treatment for women with PCOS. The outcomes include ovulation (not discussed here), clinical pregnancy and live birth rates. Pooled relative risks (RRs) were calculated using a random effects model.
Results
Thirty-eight trials were included with total participants of 3495. The number of participants in the studies ranged from 16 to 626. The duration of the trials ranged from 4 to 48 weeks; the median daily dose of metformin was 1500 mg. Pregnancy was reported by 24 trials and the live birth rate was reported by 14 trials.
Clinical pregnancy rates were improved for metformin versus placebo [pooled RR: 1.85, 95% confidence interval (CI): 1.05 -3.26, 8 trials, 707 women] and for metformin and clomiphene versus clomiphene alone (pooled RR: 1.46, 95% CI: 1.03 -2.08, 11 trials, 1208 women).
However, there was no evidence that metformin improved live birth rates, whether it was used alone (pooled RR: 1.65, 95% CI: 0.50 -5.40, 3 trials, 115 women) or in combination with clomiphene (pooled RR: 1.13, 95% CI: 0.82 -1.55, 7 trials, 907 women) (Fig. 1) .
In the studies that compared metformin and clomiphene alone, there was evidence of a decrease in the live birth rate (pooled RR: 0.36, 95% CI: 0.22 -0.58, 2 trials, 500 women) and clinical pregnancy rate (pooled RR: 0.42, 95% 0.28 -0.63, 2 trials, 500 women) in the group of obese women who took metformin. For the two trials comparing metformin and clomiphene in non-obese women, data were too heterogeneous to be pooled.
Conclusion
Metformin improves pregnancy rates when compared with placebo, and in addition to clomiphene compared with clomiphene alone, but not when compared directly with clomiphene. Metformin does not improve live birth whether it is used alone or in combination with clomiphene. Thus, the benefit of metformin in the improvement of reproductive outcomes in women with PCOS appears limited.
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